Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade D 16.5 2.29% 0.37
SGMO closed up 2.29 percent on Friday, June 22, 2018, on 1.46 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical SGMO trend table...

Date Alert Name Type % Chg
Jun 22 50 DMA Resistance Bearish 0.00%
Jun 22 MACD Bullish Centerline Cross Bullish 0.00%
Jun 22 Inside Day Range Contraction 0.00%
Jun 21 Bearish Engulfing Bearish 2.29%
Jun 21 Downside 200 DMA Break Bearish 2.29%
Jun 21 Fell Below 50 DMA Bearish 2.29%
Jun 21 MACD Bearish Centerline Cross Bearish 2.29%
Jun 21 Expansion Pivot Sell Setup Bearish Swing Setup 2.29%
Jun 21 Wide Range Bar Range Expansion 2.29%
Jun 21 Upper Bollinger Band Walk Strength 2.29%

Older signals for SGMO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.5
52 Week Low 8.0
Average Volume 2,485,708
200-Day Moving Average 17.3419
50-Day Moving Average 16.5111
20-Day Moving Average 16.2015
10-Day Moving Average 16.153
Average True Range 1.0188
ADX 17.77
+DI 25.67
-DI 21.46
Chandelier Exit (Long, 3 ATRs ) 15.7936
Chandelier Exit (Short, 3 ATRs ) 18.1064
Upper Bollinger Band 17.3655
Lower Bollinger Band 15.0375
Percent B (%b) 0.63
BandWidth 14.36904
MACD Line 0.0067
MACD Signal Line -0.1183
MACD Histogram 0.125
Fundamentals Value
Market Cap 1.38 Billion
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -20.37
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.48
Resistance 3 (R3) 17.43 17.07 17.31
Resistance 2 (R2) 17.07 16.82 17.09 17.26
Resistance 1 (R1) 16.78 16.66 16.93 16.83 17.20
Pivot Point 16.42 16.42 16.49 16.44 16.42
Support 1 (S1) 16.13 16.17 16.28 16.18 15.80
Support 2 (S2) 15.77 16.01 15.79 15.74
Support 3 (S3) 15.48 15.77 15.69
Support 4 (S4) 15.53